Ulrike Hövelmann - Concepedia

Concepedia

Author

Ulrike Hövelmann

Profil Institute for Metabolic Research ORCID

Also Known As

U Hövelmann, U. Hövelmann, ULRIKE HOVELMANN, ULRIKE HÖVELMANN, Ulrike Hovelmann, Ulrike Hövelmann

50

Publications

1.2K

Citations

18

H-Index

9

Concepts

All Affiliations

Profil Institute for Metabolic Research Novo Nordisk (Denmark)Zealand Pharma (Denmark)Eli Lilly (United States)

UH

About

Ulrike Hövelmann is an author at Profil Institute for Metabolic Research specializing in diabetes, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	120
2	Diabetes	3	3	120
3	Pharmacology	3	3	120
4	Endocrinology	2	2	80
5	Health Sciences	1	1	48

Ulrike Hövelmann

×

21

Publications

1.2K

Citations

18

H-Index

	Year	Citations
Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control Susanne Famulla, Ulrike Hövelmann, Annelie Fischer, Diabetes Care	2016	159
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine Tim Heise, Ulrike Hövelmann, Leszek Nosek, Expert Opinion on Drug Metabolism & Toxicology	2015	146
Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart Tim Heise, Ulrike Hövelmann, Lise Brøndsted, Diabetes Obesity and Metabolism	2015	144
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog Ulrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen, Diabetes Care	2017	108
Microneedle-Based Intradermal Versus Subcutaneous Administration of Regular Human Insulin or Insulin Lispro: Pharmacokinetics and Postprandial Glycemic Excursions in Patients with Type 1 Diabetes Ronald J. Pettis, Laurence Hirsch, Christoph Kapitza, Diabetes Technology & Therapeutics	2011	72
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus Tim Heise, Kirstine L. Stender-Petersen, Ulrike Hövelmann, Clinical Pharmacokinetics	2016	68
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial Helle Linnebjerg, Qianyi Zhang, Elizabeth LaBell, Clinical Pharmacokinetics	2020	55
Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial Thomas R. Pieber, Ronnie Aronson, Ulrike Hövelmann, Diabetes Care	2021	52
237-OR: Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes Ulrike Hövelmann, Lise Brøndsted, Niels Rode Kristensen, Diabetes Metabolic SyndromeDiabetes ManagementInsulin IcodecMedicineInsulin Analog Suited	2020	48
Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy Volunteers Sabine Arnolds, Klaus Rave, Ulrike Hövelmann, Experimental and Clinical Endocrinology & Diabetes	2010	41

Page 1